Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy

Inclusion Criteria:

Patients 18 years of age or older.
Pathologically documented diagnosis of Chronic Phase CML (Ph+) in whom treating physician has determined that treatment with imatinib or nilotinib is appropriate
Patients currently receiving Gleevec (imatinib) 300-600 mg daily or Tasigna (nilotinib) 300-400 mg twice daily
Known performance status 0,1 or 2 (ECOG)
Known adequate end organ function, defined as:

Total bilirubin < 1.5 xULN SGOT and SGPT <2.5 x ULN ANC > 1.5 Platlets > 100,000

Patient is willing and able to use a cell phone
Written, voluntary informed consent

Exclusion Criteria:

Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent